Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.

An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International.

At least 90% of drugs from the list of vital medicines in Russia will be of domestic origin already by the end of 2025, ...

US pharma major AbbVie has announced a deal with Xilio Therapeutics, more than doubling the latter’s share price.

Biogen reported fourth-quarter 2024 earnings that surpassed analysts' expectations, driven by strong sales of new product ...

US biotech major Gilead Sciences was trading nearly 5% higher in Wednesday’s pre-market trading after presenting its fourth ...

US biotech Voyager Therapeutics saw its shares close down 21% at $4.20 on Tuesday, after it revealed its decision to assess ...

England’s National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) have formed the Health Economics Methods Advisory (HEMA) initiative. The goal of HEMA is to ...

Belgium’s largest drugmaker UCB today released long-term data from the BE HEARD^ trials for Bimzelx (bimekizumab) in moderate ...

Privately-held Alloy Therapeutics has announced a new multi-year collaboration with Pfizer to develop a bespoke platform that ...

A federal judge has temporarily blocked the National Institutes of Health (NIH) from implementing research funding cuts in 22 ...

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech’s litifilimab.